Symbiotec Pharmalab IPO is a Mainboard Book Built public issue by Symbiotec Pharmalab Limited. The public issue comprises a fresh issue of equity shares aggregating up to ₹150 crore and an Offer for Sale of up to 1,62,65,182 equity shares. At the upper price band, the total Symbiotec Pharmalab IPO issue size is ₹1,757 crore. The company’s equity shares are proposed to be listed on both BSE and NSE.
Symbiotec Pharmalab IPO Price has been fixed in the range of ₹938 to ₹988 per equity share with a face value of ₹2 per share. The IPO opens for subscription on 24 August 2026 and closes on 27 August 2026. The basis of allotment is scheduled for 28 August 2026, refunds and share credit are scheduled for 31 August 2026, and the proposed listing date is 1 September 2026.
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. The company develops and manufactures active pharmaceutical ingredients, nutritional ingredients and specialty products for pharmaceutical, nutraceutical and wellness applications.
The company has a strong focus on corticosteroid and steroidal-hormone APIs. Its business is supported by manufacturing capabilities, research and development, process technologies and a vertically integrated operating model. The company has also been expanding into biotechnology, fermentation, complex injectables and other specialised pharmaceutical products.
Symbiotec’s products are supplied to domestic and international pharmaceutical customers. The company has developed capabilities across multiple technologies, including organic synthesis, biotransformation, fermentation and complex injectable manufacturing.
The pharmaceutical industry continues to benefit from increasing healthcare expenditure, demand for generic medicines, growth in pharmaceutical manufacturing, outsourcing of API production and increasing demand for specialised drug ingredients. India’s position as a global pharmaceutical manufacturing hub also creates opportunities for API and specialty pharmaceutical companies.
However, pharmaceutical businesses are exposed to regulatory requirements, product quality standards, pricing pressure, raw-material costs, customer concentration, intellectual property considerations and changes in global pharmaceutical markets. Investors should carefully evaluate these factors along with the company’s financial performance and valuation before making an investment decision.
IPO Details
| Information | Details |
|---|---|
| IPO Name | Symbiotec Pharmalab IPO |
| Company Name | Symbiotec Pharmalab Limited |
| IPO Type | Book Built Issue |
| IPO Category | Mainboard IPO |
| Face Value | ₹2 Per Equity Share |
| Price Band | ₹938 to ₹988 Per Share |
| Issue Size | ₹1,757 Crore |
| Fresh Issue | ₹150 Crore |
| Offer for Sale | Up to 1,62,65,182 Equity Shares |
| Total Shares Offered | Up to 1,77,83,400 Equity Shares |
| IPO Open Date | 24 August 2026 |
| IPO Close Date | 27 August 2026 |
| Anchor Investor Bidding | 21 August 2026 |
| Basis of Allotment | 28 August 2026 |
| Refund Initiation | 31 August 2026 |
| Shares Credited to Demat Account | 31 August 2026 |
| Listing Date | 1 September 2026 |
| Listing Exchange | BSE & NSE |
| Lot Size | 15 Equity Shares |
| Retail Minimum Investment | ₹14,820 |
| Retail Maximum Investment | ₹1,92,660 |
| S-HNI Minimum Investment | ₹2,07,480 |
| B-HNI Minimum Investment | ₹10,07,760 |
| Registrar | MUFG Intime India Private Limited |
| Book Running Lead Managers | JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory & Securities (India) Private Limited |
The company proposes to utilise ₹112.50 crore from the net proceeds of the fresh issue towards prepayment and/or repayment, in full or in part, of certain outstanding borrowings. The remaining net proceeds are proposed to be used for general corporate purposes.
The proceeds from the Offer for Sale will be received by the respective selling shareholders and will not accrue to the company.
Symbiotec Pharmalab IPO Dates
| IPO Event | Date |
|---|---|
| Anchor Investor Bidding | 21 August 2026 |
| IPO Opening Date | 24 August 2026 |
| IPO Closing Date | 27 August 2026 |
| Basis of Allotment | 28 August 2026 |
| Refund Initiation | 31 August 2026 |
| Shares Credited to Demat Account | 31 August 2026 |
| Listing Date | 1 September 2026 |
The Symbiotec Pharmalab IPO Allotment is scheduled to be finalised on 28 August 2026. Successful applicants are expected to receive allotted shares in their demat accounts on 31 August 2026 before the proposed listing on 1 September 2026.
Symbiotec Pharmalab IPO Reservation
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | 50% |
| Non-Institutional Investors (NII) | 15% |
| Retail Individual Investors (RII) | 35% |
An employee reservation is also provided in the issue, with an employee discount of ₹90 per equity share for eligible employees bidding in the employee reservation portion.
The final allocation under each investor category will depend on the number of valid applications received during the IPO subscription period.
Symbiotec Pharmalab IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 Lot | 15 Shares | ₹14,820 |
| Retail Maximum | 13 Lots | 195 Shares | ₹1,92,660 |
| S-HNI Minimum | 14 Lots | 210 Shares | ₹2,07,480 |
| S-HNI Maximum | 67 Lots | 1,005 Shares | ₹9,92,940 |
| B-HNI Minimum | 68 Lots | 1,020 Shares | ₹10,07,760 |
The application amounts shown above are calculated using the upper Symbiotec Pharmalab IPO Price of ₹988 per equity share. One IPO lot consists of 15 shares.
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is a pharmaceutical and biotechnology company incorporated in 2002 and headquartered in Indore, Madhya Pradesh. The company operates as a research-driven and science-based pharmaceutical manufacturer with capabilities across organic chemistry, biotechnology and complex injectables.
The company primarily operates in the pharmaceutical ingredients and specialty products market. Its portfolio includes corticosteroid APIs, steroidal-hormone APIs, nutritional ingredients and other specialty pharmaceutical products.
Symbiotec has developed specialised capabilities in the manufacture of complex pharmaceutical ingredients. Its operations combine research and development with manufacturing capabilities and process technologies.
The company has established a global customer base and supplies products to pharmaceutical markets in India and overseas. Its focus on specialised APIs provides exposure to pharmaceutical applications where technical expertise, manufacturing capabilities and regulatory compliance are important.
Symbiotec has also been investing in technologies such as biotransformation, precision fermentation and continuous flow chemistry. These technologies are intended to improve manufacturing capabilities and support development of complex pharmaceutical products.
The company’s business model is supported by long-standing customer relationships, vertically integrated manufacturing and continued investment in research and development.
Business Operations
Symbiotec Pharmalab operates across multiple pharmaceutical and biotechnology platforms.
- Corticosteroid APIs – The company manufactures corticosteroid active pharmaceutical ingredients used in pharmaceutical formulations.
- Steroidal-Hormone APIs – It manufactures steroidal-hormone APIs for pharmaceutical applications.
- Organic Chemistry – The company has capabilities in organic synthesis and related pharmaceutical manufacturing processes.
- Biotechnology – It operates biotechnology capabilities including fermentation and biotransformation technologies.
- Complex Injectables – The company is developing capabilities in complex injectable pharmaceutical products.
- Nutritional Ingredients – It manufactures ingredients used in nutraceutical and wellness applications.
- Specialty Products – The company develops specialised pharmaceutical ingredients and products.
- Research & Development – R&D is an important part of the company’s strategy for developing new products and improving manufacturing processes.
- Continuous Flow Chemistry – The company has adopted continuous flow chemistry as part of its technology platform.
- Biotransformation – Biotransformation capabilities support the development and manufacturing of selected pharmaceutical ingredients.
- Fermentation – The company has fermentation capabilities for biotechnology-based products.
- International Business – Symbiotec supplies pharmaceutical products to customers across international markets.
- CDMO Opportunities – Its R&D and manufacturing capabilities provide opportunities to expand contract development and manufacturing services.
- Vertically Integrated Manufacturing – Integration across manufacturing processes supports control over product quality and production capabilities.
Industry Overview
India’s pharmaceutical industry has established a strong position in global healthcare supply chains. The country is a major manufacturer of generic medicines and pharmaceutical ingredients and continues to attract investment into pharmaceutical manufacturing.
Demand for APIs is supported by the global requirement for medicines, increasing healthcare spending, expansion of generic drugs and the growth of pharmaceutical manufacturing in emerging markets.
Specialty APIs can offer additional opportunities because they may require specialised manufacturing capabilities, regulatory approvals, technical expertise and complex production processes.
The global pharmaceutical industry is also increasingly focused on supply-chain diversification. This can create opportunities for Indian manufacturers that can meet international quality and regulatory requirements.
India’s growing biotechnology ecosystem provides additional opportunities for companies with capabilities in fermentation, biotransformation and advanced pharmaceutical technologies.
The complex injectables segment also offers potential growth opportunities because of increasing demand for specialised drug-delivery systems and difficult-to-manufacture pharmaceutical products.
However, pharmaceutical manufacturers face stringent regulatory requirements. Manufacturing facilities can be subject to inspections and audits by regulators and customers. Product quality, compliance, environmental standards and timely regulatory approvals are therefore critical.
Companies are also exposed to raw-material prices, foreign-exchange movements, customer concentration, pricing pressure and changing pharmaceutical regulations.
Business Strategy
Symbiotec Pharmalab’s strategy focuses on strengthening its leadership in steroidal APIs while expanding into biotechnology, complex injectables, specialty ingredients and other high-value pharmaceutical products.
The company aims to leverage its scientific expertise and manufacturing infrastructure to enter additional product categories and therapeutic applications.
Expansion of biotechnology capabilities is another area of focus. The company is developing fermentation and biotechnology-based products while exploring new pharmaceutical and nutritional applications.
The company also plans to develop complex injectable products, which can provide access to higher-value pharmaceutical markets.
Continued investment in research and development remains central to the company’s strategy. R&D capabilities allow Symbiotec to develop new products, improve manufacturing processes and address increasingly complex pharmaceutical requirements.
The company also intends to leverage its integrated manufacturing platform to expand its addressable market and develop differentiated products.
Expansion of international markets is another important opportunity. The company’s existing global customer relationships provide a foundation for increasing exports and entering additional markets.
The company also has opportunities to expand its CDMO activities by using its research, development and manufacturing capabilities to support pharmaceutical customers.
Symbiotec Pharmalab IPO Financial Information
Financial performance provides important insights into the company’s revenue growth, profitability, assets and capital structure.
Symbiotec Pharmalab reported total income of ₹723.33 crore in FY2024, ₹755.98 crore in FY2025 and ₹872.26 crore in FY2026.
Profit after tax stood at ₹100.06 crore in FY2024, declined to ₹96.79 crore in FY2025 and increased to ₹109.90 crore in FY2026.
EBITDA increased from ₹177.04 crore in FY2024 to ₹206.11 crore in FY2025 and ₹231.97 crore in FY2026.
Net worth increased from ₹720.68 crore in FY2024 to ₹821.15 crore in FY2025 and ₹1,158.64 crore in FY2026. Total borrowings were ₹387.91 crore at the end of FY2026.
Symbiotec Pharmalab Financial Summary
| Particulars | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Total Income | ₹723.33 Crore | ₹755.98 Crore | ₹872.26 Crore |
| EBITDA | ₹177.04 Crore | ₹206.11 Crore | ₹231.97 Crore |
| Profit Before Tax | To be updated | To be updated | To be updated |
| Profit After Tax (PAT) | ₹100.06 Crore | ₹96.79 Crore | ₹109.90 Crore |
| Net Worth | ₹720.68 Crore | ₹821.15 Crore | ₹1,158.64 Crore |
| Total Assets | ₹1,294.79 Crore | ₹1,579.65 Crore | ₹1,780.79 Crore |
| Total Borrowings | ₹247.21 Crore | ₹540.92 Crore | ₹387.91 Crore |
The company’s total income increased by approximately 20.59% between FY2024 and FY2026.
PAT increased from ₹100.06 crore in FY2024 to ₹109.90 crore in FY2026, despite a decline during FY2025.
EBITDA increased steadily across the three reported financial years, reaching ₹231.97 crore in FY2026.
The company’s net worth increased significantly in FY2026, while borrowings declined from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026.
The fresh issue is expected to further reduce selected borrowings, with ₹112.50 crore earmarked for repayment or prepayment of debt.
Symbiotec Pharmalab IPO Key Performance Indicators (KPIs)
| KPI | FY2026 Value |
|---|---|
| Return on Equity (ROE) | 11.19% |
| Return on Capital Employed (ROCE) | 11.56% |
| Return on Net Worth (RoNW) | 9.48% |
| EBITDA Margin | 26.59% |
| PAT Margin | 12.60% |
| Debt-to-Equity Ratio | 0.33 |
| Earnings Per Share (EPS) | ₹17.39 Post-Issue |
| Net Asset Value (NAV) Per Share | ₹184.69 |
| Price to Earnings (P/E) | 56.81x Post-Issue |
| Price to Book Value | 5.35x |
The company reported an FY2026 EBITDA margin of 26.59% and PAT margin of 12.60%.
ROE stood at 11.19%, while ROCE was 11.56%. RoNW was 9.48%.
At the upper price band, the post-issue P/E works out to approximately 56.81 times based on the disclosed post-issue earnings. The issue is valued at approximately 5.35 times its FY2026 book value based on the reported NAV of ₹184.69 per share.
Investors should compare these valuation metrics with listed pharmaceutical and biotechnology companies and consider the company’s growth prospects, profitability, business mix and risks before making an investment decision.
Objects of the Symbiotec Pharmalab IPO
The company intends to utilise the net proceeds from the fresh issue for the following purposes:
- Prepayment and/or repayment, in full or in part, of certain outstanding borrowings.
- General corporate purposes.
Approximately ₹112.50 crore is proposed to be used for repayment or prepayment of certain borrowings.
The remaining portion of the fresh issue proceeds will be used for general corporate purposes, subject to applicable regulations.
The proceeds from the Offer for Sale will be received by the respective selling shareholders and will not form part of the company’s funds.
Symbiotec Pharmalab IPO Listing Performance
Symbiotec Pharmalab IPO is proposed to list on both BSE and NSE on 1 September 2026.
| Particular | Value |
|---|---|
| Listing Exchange | BSE & NSE |
| Listing Date | 1 September 2026 |
| Issue Price | ₹988 Per Share |
| Listing Price | To be updated after listing |
| Listing Gain | To be updated after listing |
| Listing Gain (%) | To be updated after listing |
The actual listing price will depend on market demand, investor sentiment, market conditions and subscription levels.
Investors should not consider grey-market expectations as a guarantee of listing performance. Long-term returns will depend on the company’s financial performance, product development, regulatory approvals, manufacturing expansion and ability to execute its growth strategy.
Symbiotec Pharmalab IPO Subscription Status
The Symbiotec Pharmalab IPO opens for subscription on 24 August 2026 and closes on 27 August 2026.
The final subscription figures will be available after the completion of bidding. Investor participation across QIB, NII and retail categories will indicate the level of demand received by the issue.
Symbiotec Pharmalab IPO Subscription
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIB) | To be updated |
| Non-Institutional Investors (NII) | To be updated |
| Retail Individual Investors (RII) | To be updated |
| Employee Category | To be updated |
| Total Subscription | To be updated |
The final Symbiotec Pharmalab IPO Subscription Status will be updated after the issue closes on 27 August 2026.
Symbiotec Pharmalab IPO GMP
Symbiotec Pharmalab IPO GMP is an unofficial indicator of grey-market sentiment and is not regulated by SEBI, BSE or NSE.
As of 23 August 2026, the reported grey-market premium was around ₹409 per share. Against the upper Symbiotec Pharmalab IPO Price of ₹988, this indicated an unofficial estimated listing price of approximately ₹1,397 per share.
The implied premium at ₹409 was approximately 41.40% over the upper issue price.
However, grey-market premiums can change rapidly before listing and do not guarantee the actual listing price or future returns.
Investors should therefore treat Symbiotec Pharmalab IPO GMP only as an unofficial market indicator and should not base an investment decision solely on GMP.
The company’s financial performance, valuation, debt position, product portfolio, regulatory track record and long-term growth prospects remain more important factors.
Symbiotec Pharmalab IPO Review
Symbiotec Pharmalab IPO provides investors with an opportunity to invest in a research-driven pharmaceutical and biotechnology company with specialised capabilities in steroidal APIs, biotechnology and complex injectables.
The company has established a strong position in corticosteroid and steroidal-hormone APIs and operates a vertically integrated manufacturing platform.
Its business is diversified across organic chemistry, biotechnology and complex injectables. This provides opportunities to develop products across multiple pharmaceutical technologies.
One of the company’s major strengths is its specialised expertise in corticosteroid and steroidal-hormone APIs. Such products require technical manufacturing capabilities and regulatory compliance, which can create entry barriers for new competitors.
The company also has long-standing relationships with domestic and international customers. Its global presence provides access to pharmaceutical markets outside India.
Symbiotec is investing in biotechnology capabilities, fermentation, biotransformation and advanced manufacturing technologies. These investments can help the company expand beyond its traditional steroidal API business.
The complex injectables segment provides another potential growth opportunity. Entry into specialised injectable products could allow the company to address higher-value pharmaceutical applications.
Financially, the company has demonstrated revenue growth. Total income increased from ₹723.33 crore in FY2024 to ₹872.26 crore in FY2026.
EBITDA increased from ₹177.04 crore to ₹231.97 crore during the same period.
PAT increased from ₹100.06 crore to ₹109.90 crore over the two-year period, although FY2025 reported a decline before recovery in FY2026.
The company also strengthened its net worth, which increased to ₹1,158.64 crore in FY2026.
Borrowings declined from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026. The proposed use of ₹112.50 crore from the fresh issue for repayment or prepayment of borrowings could further reduce debt.
However, the IPO has a very large Offer for Sale component. Of the ₹1,757 crore issue, ₹150 crore is fresh issue while approximately ₹1,607 crore is offered for sale. Therefore, most of the IPO proceeds will go to selling shareholders rather than the company.
Valuation is another important consideration. At the upper price band, the post-issue P/E is approximately 56.81 times and the price-to-book value is approximately 5.35 times.
The company’s FY2026 RoNW of 9.48% is comparatively moderate relative to the valuation being demanded. Investors should therefore carefully assess whether future growth from new capacities, complex injectables, biotechnology and specialty products can justify the IPO valuation.
Pharmaceutical manufacturing is also subject to strict regulatory requirements. Inspections, compliance requirements, product quality standards and regulatory approvals can affect operations.
The company may also face competition from established Indian and international pharmaceutical manufacturers. Changes in raw-material prices, customer demand and global pharmaceutical markets can influence profitability.
Overall, Symbiotec Pharmalab has an established pharmaceutical platform, specialised API capabilities, international market exposure, strong EBITDA margins and opportunities for expansion into biotechnology and complex injectables.
At the same time, investors should carefully evaluate valuation, debt, regulatory risks, competition and the high proportion of Offer for Sale before making an investment decision.
Symbiotec Pharmalab IPO Strengths
- Strong expertise in corticosteroid and steroidal-hormone APIs.
- Research and development-driven pharmaceutical and biotechnology business.
- Capabilities across organic chemistry, biotechnology and complex injectables.
- Vertically integrated manufacturing platform.
- Long-standing relationships with domestic and international customers.
- Established international market presence.
- Strong EBITDA margin of 26.59% in FY2026.
- PAT margin of 12.60% in FY2026.
- Revenue growth between FY2024 and FY2026.
- EBITDA increased consistently across the reported period.
- Net worth increased significantly in FY2026.
- Borrowings declined during FY2026.
- Exposure to high-value specialty pharmaceutical products.
- Opportunities in biotechnology and fermentation.
- Potential growth from complex injectable products.
- Continued investment in research and development.
- Opportunities to expand CDMO capabilities.
Symbiotec Pharmalab IPO Risk Factors
- Pharmaceutical manufacturing is subject to strict regulatory and quality requirements.
- Manufacturing facilities may face inspections and audits from regulators and customers.
- Product quality failures could adversely affect business performance.
- The company operates in a competitive pharmaceutical industry.
- Raw-material price fluctuations can affect margins.
- Changes in global pharmaceutical demand may affect exports.
- Foreign-exchange movements can impact international operations.
- The business requires continued investment in R&D and manufacturing technologies.
- New product development may not always achieve commercial success.
- Expansion into complex injectables involves execution and regulatory risks.
- Biotechnology and fermentation projects may require significant investment.
- The company has outstanding borrowings despite the planned debt repayment.
- A substantial portion of the IPO consists of an Offer for Sale.
- Most IPO proceeds will go to selling shareholders rather than the company.
- The issue valuation is relatively high compared with the company’s RoNW.
- Changes in pharmaceutical regulations may affect product approvals and sales.
- Dependence on key customers and international markets may affect revenue.
- Competition from global pharmaceutical manufacturers could create pricing pressure.
Symbiotec Pharmalab IPO Promoters
The promoters of Symbiotec Pharmalab Limited are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
The promoter and promoter group collectively held approximately 34.47% of the company’s pre-issue equity share capital.
Anil Satwani is the Chairman and Managing Director and has been associated with the company’s pharmaceutical business for several decades.
The promoter group has played an important role in establishing and expanding the company’s pharmaceutical manufacturing and R&D capabilities.
Symbiotec Pharmalab IPO Promoters Details
| Promoter | Role |
|---|---|
| Anil Satwani | Promoter |
| Kashish Satwani | Promoter |
| Sushil Satwani | Promoter |
| Satwani Holdings LLP | Promoter Group |
The promoter and promoter group collectively held approximately 34.47% before the IPO. The post-issue holding should be considered based on the final shareholding disclosure after completion of the offer.
Symbiotec Pharmalab IPO Management Team
The company is led by a management team with experience in pharmaceutical manufacturing, finance, research and corporate management.
| Name | Designation |
|---|---|
| Anil Satwani | Chairman & Managing Director |
| Raghavender Ramachandran | Chief Financial Officer |
| Salil Jain | Company Secretary & Compliance Officer |
Anil Satwani has extensive experience in the pharmaceutical sector and has been associated with the company since its incorporation. Raghavender Ramachandran has significant experience in pharmaceutical finance and corporate management.
Symbiotec Pharmalab IPO Registrar Details
The registrar is responsible for processing IPO applications, finalising the basis of allotment, coordinating refunds, crediting shares to successful applicants and handling investor-related services.
| Particular | Details |
|---|---|
| Registrar Name | MUFG Intime India Private Limited |
| Website | https://in.mpms.mufg.com |
| IPO Allotment Status | https://in.mpms.mufg.com/Initial_Offer/public-issues.html |
| Contact Number | +91 22 4918 6000 |
| Email ID | [email protected] |
Symbiotec Pharmalab IPO Lead Manager Details
The Book Running Lead Managers are responsible for managing the IPO process, coordinating regulatory requirements and assisting the company throughout the public issue.
| Particular | Details |
|---|---|
| Lead Manager 1 | JM Financial Limited |
| Lead Manager 2 | Avendus Capital Private Limited |
| Lead Manager 3 | Motilal Oswal Investment Advisors Limited |
| Lead Manager 4 | Nomura Financial Advisory & Securities (India) Private Limited |
The lead managers coordinate the issue process with the company, stock exchanges, regulators, investors and other intermediaries.
Symbiotec Pharmalab Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | Symbiotec Pharmalab Limited |
| Registered Office | 385/2, Pigdamber, Rau, Indore – 453331, Madhya Pradesh, India |
| Website | https://symbiotec.com |
| Email ID | [email protected] |
| Contact Number | +91 731 667 6405 |
The company’s registered and corporate office is located in Pigdamber, Rau, Indore, Madhya Pradesh.
How to Check Symbiotec Pharmalab IPO Allotment Status
Investors can check the Symbiotec Pharmalab IPO Allotment Status after the basis of allotment is finalised through the registrar’s website or stock exchange facilities.
Through MUFG Intime India Private Limited
- Visit the official MUFG Intime IPO allotment portal.
- Select Symbiotec Pharmalab IPO from the IPO list.
- Choose PAN Number, Application Number or DP/Client ID.
- Enter the required details.
- Submit the information to view the allotment status.
Through BSE
- Visit the official BSE IPO application status facility.
- Select the relevant IPO.
- Enter the PAN Number or application details.
- Complete the required verification.
- Submit the details to check the allotment status.
Through NSE
- Visit the official NSE IPO bid verification facility.
- Select the relevant IPO.
- Enter the required application details.
- Complete the verification process.
- Submit the details to view the application status.
The Symbiotec Pharmalab IPO Allotment is scheduled for 28 August 2026, with refunds and demat credit scheduled for 31 August 2026. The proposed listing date is 1 September 2026.
Symbiotec Pharmalab IPO Conclusion
Symbiotec Pharmalab IPO provides investors with an opportunity to invest in a specialised pharmaceutical and biotechnology company with capabilities across steroidal APIs, organic chemistry, biotechnology and complex injectables.
The company has established expertise in corticosteroid and steroidal-hormone APIs and has developed a vertically integrated manufacturing platform supported by research and development capabilities.
Its expansion into biotechnology, fermentation, complex injectables, specialty products and advanced pharmaceutical technologies provides opportunities for future growth.
Financial performance has shown improvement over the longer period. Total income increased from ₹723.33 crore in FY2024 to ₹872.26 crore in FY2026, while EBITDA increased from ₹177.04 crore to ₹231.97 crore.
PAT stood at ₹109.90 crore in FY2026, while net worth increased to ₹1,158.64 crore.
The company also reduced borrowings during FY2026 and proposes to use ₹112.50 crore of the fresh issue proceeds for repayment or prepayment of certain outstanding borrowings.
However, investors should carefully consider the valuation. At the upper price band of ₹988, the post-issue P/E is approximately 56.81 times and price-to-book value is approximately 5.35 times.
The large Offer for Sale component is another important consideration because approximately ₹1,607 crore of the ₹1,757 crore issue represents shares being sold by existing shareholders.
The pharmaceutical industry also involves regulatory, quality, manufacturing, competitive and international-market risks.
Symbiotec Pharmalab IPO GMP has indicated positive grey-market sentiment, but GMP is unofficial and does not guarantee the listing price or future returns.
Overall, Symbiotec Pharmalab has a specialised business model, established API capabilities, international exposure, healthy operating margins and opportunities to expand into new pharmaceutical technologies. Investors should evaluate the company’s valuation, financial performance, growth plans and risk factors carefully before making an investment decision.
Symbiotec Pharmalab IPO FAQs
What is Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO is the Mainboard public issue of Symbiotec Pharmalab Limited, a pharmaceutical and biotechnology company engaged in APIs, nutritional ingredients, specialty products and complex pharmaceutical technologies.
What is the Symbiotec Pharmalab IPO Price?
The Symbiotec Pharmalab IPO Price band is ₹938 to ₹988 per equity share.
What is the issue size of Symbiotec Pharmalab IPO?
The total issue size is ₹1,757 crore, comprising a fresh issue of ₹150 crore and an Offer for Sale of up to 1,62,65,182 equity shares.
What is the Symbiotec Pharmalab IPO Lot Size?
The Symbiotec Pharmalab IPO Lot Size is 15 shares. At the upper price band of ₹988, the minimum retail investment is ₹14,820.
When does Symbiotec Pharmalab IPO open and close?
The IPO opens on 24 August 2026 and closes on 27 August 2026.
What is the Symbiotec Pharmalab IPO GMP?
The reported Symbiotec Pharmalab IPO GMP was around ₹409 per share as of 23 August 2026. GMP is unofficial and can change before listing, so it should not be treated as a guarantee of listing gains.
What is the Symbiotec Pharmalab IPO Subscription Status?
The Symbiotec Pharmalab IPO Subscription Status will be updated as investor bidding progresses during the issue period. The final subscription figures will be available after the IPO closes.
When is the Symbiotec Pharmalab IPO Allotment?
The Symbiotec Pharmalab IPO Allotment is scheduled for 28 August 2026. Refunds and demat credit are scheduled for 31 August 2026.
Who is the registrar for Symbiotec Pharmalab IPO?
MUFG Intime India Private Limited is the registrar to the Symbiotec Pharmalab IPO.
What does Symbiotec Pharmalab Limited do?
Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company with capabilities in organic chemistry, biotechnology and complex injectables. It manufactures corticosteroid and steroidal-hormone APIs along with nutritional ingredients and specialty pharmaceutical products.
